MoonLake Immunotherapeutics (MLTX) Q3 2025 earnings summary

Executive summary

• Focused on developing Sonelokimab (SLK), a tri-specific IL-17A/F inhibiting Nanobody for inflammatory skin and joint diseases, with multiple ongoing Phase 3 and Phase 2 trials in HS, PsA, PPP, and axSpA.

• Released new data from multiple clinical trials of SLK, showing significant clinical benefits in PPP and HS.

• VELA-1 Phase 3 trial in HS met its primary endpoint, but VELA-2 narrowly missed due to high placebo response; FDA Type B meeting set for December 2025 to discuss BLA submission, with a potential commercial launch in 2027.

• No products approved or revenue from product sales; expects continued significant operating losses as clinical programs advance.

Financial highlights

• Net loss for Q3 2025 was $70.7 million, up 95.8% year-over-year; nine-month net loss was $167.3 million, up 123.5%.

• Research and development expenses rose 69.7% to $60.6 million for Q3 and 102.8% to $146.9 million for the nine months, driven by expanded clinical trials and manufacturing.

• General and administrative expenses increased 46.4% to $10.8 million for Q3 and 55.3% to $32.8 million for the nine months, reflecting higher personnel and advisory costs.

• Cash and cash equivalents plus short-term marketable securities totaled $380.5 million as of September 30, 2025.

Outlook and guidance

• Cash position and committed debt facility expected to fund operations into the second half of 2027.

• Plans to submit a BLA for SLK in late 2026, with a potential U.S. commercial launch in 2027, subject to regulatory approval.

• Key upcoming milestones: FDA Type B meeting in December 2025, multiple Phase 2 and 3 trial readouts, and BLA submission in 2026.

• Expects continued high R&D and G&A expenses as clinical programs and pre-commercial activities progress.